¼¼°èÀÇ ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå
Peptide and Oligonucleotide CDMO
»óǰÄÚµå : 1782997
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 370 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ¼¼°è ½ÃÀåÀº 2030³â±îÁö 57¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 28¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 12.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 57¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÆéŸÀ̵å´Â CAGR 14.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 42¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 9.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 7¾ï 5,230¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 17.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀº 2024³â¿¡ 7¾ï 5,230¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 12¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 17.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 9.2%¿Í 11.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO¶õ?

ÆéŸÀ̵å-¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå °³¹ß Á¦Á¶ À§Å¹±â°ü(CDMO)Àº ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµåÀÇ °³¹ß ¹× Á¦Á¶¸¦ Àü¹®À¸·Î ÇÏ´Â ±â¾÷ÀÔ´Ï´Ù. ÀÌµé ¹ÙÀÌ¿ÀÀǾàǰÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, À¯ÀüÁúȯ, ¹ÙÀÌ·¯½º °¨¿° µî ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·áÁ¦ °³¹ß¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMOÀÇ ¿ªÇÒÀº ÀÌ·¯ÇÑ º¹ÀâÇÑ ºÐÀÚÀÇ ¿¬±¸, °³¹ß, ´ë·® »ý»ê¿¡ ´ëÇÑ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º¿¡´Â ÀϹÝÀûÀ¸·Î ½Å¾à °³¹ß, °øÁ¤ °³¹ß, Á¦Á¶ ¹× »ó¾÷È­ Áö¿øÀÌ Æ÷ÇԵǾî Á¦Ç°ÀÌ Á¦¾à »ê¾÷ÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ÃæÁ·Çϵµ·Ï º¸ÀåÇÕ´Ï´Ù.

ÆéŸÀ̵å ÀǾàǰÀº ±âÁ¸ ÀúºÐÀÚ ÀǾàǰ¿¡ ºñÇØ ƯÀ̼ºÀÌ ³ô°í µ¶¼ºÀÌ ³·¾Æ Å« È£ÀÀÀ» ¾ò°í ÀÖ½À´Ï´Ù. ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå´Â RNA ±â¹Ý Ä¡·áÁ¦ ¹× ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¿Í °°Àº Á¦Ç°À» Æ÷ÇÔÇÏ¿© À¯ÀüÀÚ ¹ßÇöÀ» Ç¥ÀûÈ­Çϰí Á¶ÀýÇÒ ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¿¡ ƯȭµÈ CDMO´Â Á¦¾àȸ»ç°¡ ÀÌ·¯ÇÑ °íµµ·Î Àü¹®È­µÈ ºÐÀÚ¸¦ Á¦Á¶ÇÏ´Â µ¥ ÀÖ¾î ¾î·Á¿òÀ» ±Øº¹ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¿©±â¿¡´Â È®À强, ¼øµµ, ¼öÀ² ÃÖÀûÈ­, ±ÔÁ¦ Áؼö º¸Àå µîÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ. ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ±â¹Ý ÀǾàǰ ½ÃÀåÀÌ Áö¼ÓÀûÀ¸·Î È®´ëµÊ¿¡ µû¶ó ÀÌ ºÐ¾ßÀÇ CDMO ¼­ºñ½º ¼ö¿ä´Â Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÌ È®´ëµÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀº »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸ÂÃãÇü ÀÇ·áÀÇ ºÎ»ó, RNA Ä¡·áÀÇ ¹ßÀü, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °¡Àå µÎµå·¯Áø ÃËÁø¿äÀÎ Áß Çϳª´Â »ý¹°ÇÐÀû Á¦Á¦, ƯÈ÷ ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ »ý¹°ÇÐÀû Á¦Á¦´Â ƯÀ̼ºÀÌ ³ô°í, ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç, Èñ±Í À¯ÀüÁúȯ, ƯÁ¤ ¾Ï, ¹ÙÀÌ·¯½º °¨¿° µî ÀÌÀü¿¡´Â Ä¡·á°¡ ¾î·Á¿ü´ø Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

RNA ±â¹Ý Ä¡·á¹ýÀÇ ¹ßÀüµµ ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. COVID-19 ÆÒµ¥¹Í¿¡ ´ëÇÑ mRNA ¹é½ÅÀÇ ¼º°øÀº ÀÇ·á ºÐ¾ß¿¡¼­ RNA ±â¼úÀÇ ÀáÀç·ÂÀ» ºÎ°¢½ÃÄ×½À´Ï´Ù. ±× °á°ú, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ mRNA ¹é½Å, À¯ÀüÀÚ ÆíÁý µµ±¸, RNA °£¼· ¿ä¹ý µîÀÇ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç ¹× »ý¸í°øÇÐ ±â¾÷µéÀº ÀÌ·¯ÇÑ º¹ÀâÇÑ ºÐÀÚÀÇ Á¦Á¶ ¹× °³¹ß¿¡ Á¤ÅëÇÑ CDMO ÆÄÆ®³Ê¸¦ ã°í ÀÖ½À´Ï´Ù. ¼ÒºÐÀÚ °£¼· RNA(siRNA), ¸Þ½ÅÀú RNA(mRNA), ¾ÈƼ¼¾½º ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå(ASO)¸¦ Æ÷ÇÔÇÑ ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¿¡ ´ëÇÑ ¼ö¿ä´Â RNA Ä¡·áÁ¦ ¿¬±¸°¡ È®´ëµÊ¿¡ µû¶ó »ó½Â¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ¾Ï, ´ç´¢º´, ½ÉÇ÷°üÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ Æ÷ÇÔÇÑ »õ·Î¿î Ä¡·á Á¢±Ù¹ýÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó ÀÌ·¯ÇÑ Áúº´ÀÇ ±Ùº»ÀûÀÎ ¿øÀÎÀ» ºÐÀÚ ¼öÁØ¿¡¼­ Ç¥ÀûÀ¸·Î »ï´Â Çõ½ÅÀûÀÎ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÓ»ó ¹× »ó¾÷È­ ´Ü°è¿¡ ÁøÀÔÇÏ´Â ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ±â¹Ý ÀǾàǰ Èĺ¸¹°ÁúÀÇ ¼ö°¡ Áõ°¡Çϸ鼭 CDMO°¡ Á¦°øÇÏ´Â Àü¹® Á¦Á¶ ¹× °³¹ß ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÆéŸÀÌµå ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMOÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ÁÖ¿ä µ¿ÇâÀº ¹«¾ùÀΰ¡?

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ ¹Ì·¡´Â Á¦Á¶ ±â¼úÀÇ ¹ßÀü, ǰÁú ¹× ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ Á߿伺 Áõ°¡, È®À强°ú À¯¿¬¼º¿¡ ´ëÇÑ °ü½É Áõ°¡ µî ¸î °¡Áö º¯È­ÇÏ´Â Ãß¼¼¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. Áß¿äÇÑ Æ®·»µå Áß Çϳª´Â ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ±â¼úÀÇ ¹ßÀüÀ¸·Î º¸´Ù ½Å¼ÓÇϰí È¿À²ÀûÀÌ¸ç ºñ¿ë È¿À²ÀûÀÎ Á¦Á¶ °øÁ¤ÀÌ °¡´ÉÇØÁ³´Ù´Â Á¡ÀÔ´Ï´Ù. °íü»ó ÆéŸÀ̵å ÇÕ¼º(SPPS), ¿¬¼Ó È帧 È­ÇÐ, ÀÚµ¿È­ ÇÏÀ̽º·çDz ½Ã½ºÅÛ µîÀÇ ±â¼ú Çõ½ÅÀ¸·Î °íǰÁú ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ ´ë±Ô¸ð·Î »ý»êÇÒ ¼ö ÀÖ´Â ´É·ÂÀÌ Çâ»óµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù.

¶ÇÇÑ, ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå¸¦ Æ÷ÇÔÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ±ÔÁ¦ ȯ°æÀº ´õ¿í ¾ö°ÝÇØÁö°í ÀÖÀ¸¸ç, CDMO°¡ ǰÁú °ü¸® Á¶Ä¡¸¦ °­È­ÇÏ°í ¼¼°è ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇÒ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ¹Ì±¹ FDA³ª À¯·´ÀǾàǰû(EMA)°ú °°ÀÌ »ý¹°ÇÐÀû Á¦Á¦ÀÇ °³¹ß, Á¦Á¶, À¯Åë¿¡ ´ëÇÑ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» °¡Áö°í ÀÖ´Â ±ÔÁ¦±â°üÀÇ ¿ä±¸»çÇ×À» ÃæÁ·ÇÏ´Â °Íµµ Æ÷ÇԵ˴ϴÙ. »ý¹°ÇÐÀû Á¦Á¦ÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó CDMO´Â ÁøÈ­ÇÏ´Â ±ÔÁ¦ Ç¥ÁØÀ» ¹Ì¸® ÆÄ¾ÇÇϰí, Á¦Á¶ °øÁ¤ÀÌ ¿Ïº®ÇÏ°Ô ÁؼöÇϰí ÃÖ°í ¼öÁØÀÇ ¼øµµ¿Í È¿´ÉÀ» °¡Áø Ä¡·áÁ¦¸¦ »ý»êÇÒ ¼ö ÀÖµµ·Ï ¸ð¹ü»ç·Ê¸¦ äÅÃÇØ¾ß ÇÕ´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µå´Â À¯¿¬Çϰí È®Àå °¡´ÉÇÑ Á¦Á¶ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ±â¹Ý Ä¡·áÁ¦°¡ ÀÓ»ó ÆÄÀÌÇÁ¶óÀÎÀ» ÁøÇàÇÔ¿¡ µû¶ó, ÀǾàǰ °³¹ß ±â¾÷µéÀº ÀǾàǰ °³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó È®Àå °¡´ÉÇÑ À¯¿¬ÇÑ »ý»ê´É·ÂÀ» Á¦°øÇÒ ¼ö ÀÖ´Â CDMO¸¦ ÇÊ¿ä·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯¿¬¼ºÀº Á¦¾àȸ»ç°¡ ºñ¿ë È¿À²¼º, ǰÁú, ±ÔÁ¦ Áؼö¸¦ À¯ÁöÇϸ鼭 È¿À²ÀûÀ¸·Î »ý»ê ±Ô¸ð¸¦ È®´ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¸ÂÃãÀÇ·á¿Í Ç¥ÀûÄ¡·á°¡ º¸ÆíÈ­µÊ¿¡ µû¶ó CDMO´Â °³º° ÀǾàǰ Èĺ¸¹°ÁúÀÇ °íÀ¯ÇÑ ´ÏÁ ÃæÁ·½Ãų ¼ö ÀÖ´Â ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ÀûÀÀ·ÂÀ» °®Ãç¾ß ÇÒ °ÍÀÔ´Ï´Ù.

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ ¼ºÀåÀº »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, RNA ±â¹Ý Ä¡·á¹ýÀÇ ¹ßÀü, À¯ÀüÀÚ Ç¥Àû Ä¡·á¿¡ ´ëÇÑ ¿¬±¸ Ȱ¼ºÈ­ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. Á¦¾à ¾÷°è°¡ »ý¹°ÇÐÀû Á¦Á¦·ÎÀÇ ÀüȯÀ» °è¼ÓÇϰí ÀÖ´Â °¡¿îµ¥, ÆéŸÀ̵å¿Í ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå´Â ´õ ³ôÀº Á¤È®µµ¿Í ÀûÀº ºÎÀÛ¿ëÀ¸·Î ƯÁ¤ »ý¹°ÇÐÀû °úÁ¤À» Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ´Â ´É·ÂÀ¸·Î ÀÎÇØ Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ °³¹ß Ȱµ¿ÀÌ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ±× °á°ú ÀÌ·¯ÇÑ ºÐÀÚÀÇ Á¦Á¶ ¹× ½ºÄÉÀϾ÷¿¡ ´ëÇÑ Àü¹®¼ºÀ» Á¦°øÇÒ ¼ö ÀÖ´Â Àü¹® CDMO ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

RNA ±â¹Ý Ä¡·á¹ý, ƯÈ÷ mRNA ¹é½Å°ú À¯ÀüÀÚ Ä¡·áÀÇ ±Þ¼ÓÇÑ °³¹ß°ú ½ÂÀÎÀº CDMO ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. COVID-19 mRNA ¹é½ÅÀÇ ¼º°ø¿¡ À̾î, º¸´Ù ±¤¹üÀ§ÇÑ Áúº´ Ä¡·á¿¡ RNA ±â¼úÀÇ Àû¿ëÀ» È®´ëÇÏ´Â °Í¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå ÇÕ¼º ¹× RNA »ý»ê¿¡ ÀÖ¾î °íµµÀÇ ´É·ÂÀ» °®Ãá CDMO¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. RNA ±â¹Ý Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀÌ ¼ºÀåÇÔ¿¡ µû¶ó, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå »ý»ê Àü¹® CDMO´Â ÀÓ»ó½ÃÇè ¹× »ó¾÷Àû Ãâ½Ã¸¦ À§ÇØ »ý»êÀ» È®´ëÇÏ´Â Á¦¾à»ç¸¦ Áö¿øÇÒ ¼ö ÀÖ´Â À¯¸®ÇÑ À§Ä¡¿¡ ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó º¸´Ù Àü¹®ÀûÀÌ°í ¼Ò±Ô¸ðÀÇ °íǰÁú ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ ¸¶Ä¿³ª Áúº´ ¾ÆÇüÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ÀǾàǰÀÇ °³¹ßÀÌ ÁøÇàµÊ¿¡ µû¶ó, ³ôÀº ǰÁúÀ» À¯ÁöÇϸ鼭 ¼Ò±Ô¸ðÀÇ ¸ÂÃãÇü ¹èÄ¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â Á¤¹Ð Á¦Á¶¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. À¯¿¬Çϰí È®Àå °¡´ÉÇÑ °íǰÁú Á¦Á¶ ´É·ÂÀ» Á¦°øÇÏ´Â CDMO´Â ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» Áö¿øÇϱâ À§ÇØ Á¡Á¡ ´õ ¸¹Àº ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼ºÁúȯÀÇ È®»ê°ú À¯ÀüÀÚ ÆíÁý Ä¡·á·ÎÀÇ ÀüȯÀº ÆéŸÀÌµå ¹× ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå CDMO ½ÃÀåÀÇ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÆéŸÀ̵å, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå), ¼­ºñ½º À¯Çü(À§Å¹»ý»ê ¼­ºñ½º, À§Å¹°³¹ß ¼­ºñ½º), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾à ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷ ÃÖÁ¾»ç¿ëÀÚ, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Peptide and Oligonucleotide CDMO Market to Reach US$5.7 Billion by 2030

The global market for Peptide and Oligonucleotide CDMO estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.7 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. Peptides, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$4.2 Billion by the end of the analysis period. Growth in the Oligonucleotides segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$752.3 Million While China is Forecast to Grow at 17.3% CAGR

The Peptide and Oligonucleotide CDMO market in the U.S. is estimated at US$752.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Peptide and Oligonucleotide CDMO Market - Key Trends & Drivers Summarized

What Is a Peptide and Oligonucleotide CDMO and How Does It Work?

A Peptide and Oligonucleotide Contract Development and Manufacturing Organization (CDMO) specializes in the development and manufacturing of peptides and oligonucleotides, which are short chains of amino acids and nucleotides, respectively. These biopharmaceutical products are crucial in the development of therapeutics for a range of diseases, including cancer, autoimmune disorders, genetic diseases, and viral infections. The role of a peptide and oligonucleotide CDMO is to provide services related to the research, development, and large-scale production of these complex molecules. These services typically include drug discovery, process development, manufacturing, and commercialization support, ensuring that the products meet the stringent regulatory requirements of the pharmaceutical industry.

Peptide drugs are gaining significant traction due to their specificity and lower toxicity compared to traditional small-molecule drugs. Oligonucleotides, which include products like RNA-based therapeutics and antisense oligonucleotides, are becoming increasingly important for their ability to target and modulate gene expression. CDMOs focused on peptides and oligonucleotides help pharmaceutical companies navigate the challenges of producing these highly specialized molecules. This includes overcoming challenges related to scalability, purity, yield optimization, and ensuring regulatory compliance. As the market for peptide and oligonucleotide-based drugs continues to expand, the demand for CDMO services in this space is poised to increase substantially.

Why Is the Peptide and Oligonucleotide CDMO Market Expanding?

The peptide and oligonucleotide CDMO market is growing due to several key factors, including the rise of biologics and personalized medicine, advances in RNA therapies, and the increasing prevalence of chronic diseases. One of the most prominent drivers is the growing shift toward biologic drugs, particularly peptides and oligonucleotides, which are considered more targeted and precise compared to traditional small-molecule drugs. These biologics offer higher specificity, fewer side effects, and can be used to treat diseases that were previously challenging to manage, such as rare genetic disorders, certain cancers, and viral infections.

The advancement of RNA-based therapies is another major factor contributing to the growth of the peptide and oligonucleotide CDMO market. The success of mRNA vaccines in combating the COVID-19 pandemic has highlighted the potential of RNA technologies in medicine. As a result, the demand for oligonucleotide manufacturing services is rapidly increasing, particularly for products like mRNA vaccines, gene-editing tools, and RNA interference therapies. Pharmaceutical companies and biotech firms are increasingly seeking CDMO partners with expertise in the production and development of these complex molecules. The demand for oligonucleotides, including small interfering RNA (siRNA), messenger RNA (mRNA), and antisense oligonucleotides (ASOs), is expected to continue its upward trajectory as research into RNA therapeutics expands.

In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is driving the need for novel therapeutic approaches, including those involving peptides and oligonucleotides. As the global population ages, there is an escalating demand for innovative drugs that target the underlying causes of these diseases at a molecular level. This has led to a growing number of peptide and oligonucleotide-based drug candidates entering the clinical and commercial stages, further increasing the demand for specialized manufacturing and development services offered by CDMOs.

What Key Trends Are Shaping the Future of Peptide and Oligonucleotide CDMOs?

The future of the peptide and oligonucleotide CDMO market is being shaped by several transformative trends, including advances in manufacturing technologies, the increasing importance of quality and regulatory compliance, and the growing focus on scalability and flexibility. One key trend is the advancement of peptide and oligonucleotide synthesis technologies, which are enabling faster, more efficient, and cost-effective manufacturing processes. Innovations in solid-phase peptide synthesis (SPPS), continuous-flow chemistry, and automated high-throughput systems are improving the ability to produce high-quality peptides and oligonucleotides at scale, which is critical for meeting the increasing global demand.

Additionally, the regulatory environment for biologics, including peptides and oligonucleotides, is becoming more stringent, driving the need for CDMOs to enhance their quality control measures and ensure compliance with global regulations. This includes meeting the requirements set by regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA), which have strict guidelines for the development, manufacturing, and distribution of biologics. As the complexity of biologics increases, CDMOs will need to stay ahead of evolving regulatory standards and adopt best practices to ensure that their manufacturing processes are fully compliant and capable of producing therapeutics with the highest levels of purity and efficacy.

Another important trend is the growing demand for flexible and scalable manufacturing solutions. As peptide and oligonucleotide-based therapeutics move through the clinical pipeline, drug developers require CDMOs that can provide flexible manufacturing capabilities that scale with the progression of the drug’s development. This flexibility is essential as it allows pharmaceutical companies to efficiently scale up production while maintaining cost-effectiveness, quality, and regulatory compliance. As personalized medicine and targeted therapies become more common, CDMOs will also need to be adaptable in offering customized solutions that can cater to the unique needs of individual drug candidates.

What Are the Key Drivers of Growth in the Peptide and Oligonucleotide CDMO Market?

The growth in the peptide and oligonucleotide CDMO market is driven by several factors, including increasing demand for biologics, advancements in RNA-based therapies, and growing research into gene-targeted treatments. As the pharmaceutical industry continues to shift toward biologic drugs, peptides and oligonucleotides have gained significant attention due to their ability to target specific biological processes with higher precision and fewer side effects. This has led to a surge in research and development activities focused on these therapeutic modalities, thereby increasing the demand for specialized CDMO services that can provide expertise in the manufacturing and scale-up of these molecules.

The rapid development and approval of RNA-based therapies, especially mRNA vaccines and gene therapies, have further fueled growth in the CDMO sector. Following the success of mRNA vaccines for COVID-19, there has been a heightened interest in expanding the application of RNA technologies to treat a broader range of diseases. This has driven the need for CDMOs with advanced capabilities in oligonucleotide synthesis and RNA production. As the pipeline for RNA-based therapeutics grows, CDMOs that specialize in oligonucleotide manufacturing are well-positioned to support pharmaceutical companies as they scale up production for clinical trials and commercial launch.

Additionally, the increasing focus on personalized medicine is driving the need for more specialized, small-scale, high-quality peptide and oligonucleotide manufacturing services. As more drugs are developed to target specific genetic markers or disease subtypes, there is a greater emphasis on precision manufacturing that can accommodate smaller, customized batches while maintaining high levels of quality. CDMOs that offer flexible, scalable, and high-quality production capabilities are increasingly in demand to support these innovations. Moreover, the growing prevalence of chronic diseases and the shift toward gene-editing therapies are contributing to the expansion of the peptide and oligonucleotide CDMO market, as these technologies offer new avenues for treating previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Peptide and Oligonucleotide CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Peptides, Oligonucleotides); Service Type (Contract Manufacturing Service, Contract Development Service); End-Use (Pharmaceutical Companies End-Use, Biopharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â